Last reviewed · How we verify
PENBRAYA — Competitive Intelligence Brief
preclinical
PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y.
Infectious Disease
Vaccine
Live · refreshed every 30 min
Target snapshot
PENBRAYA (penbraya) — Pfizer Inc.. PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PENBRAYA TARGET | penbraya | Pfizer Inc. | preclinical | PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. class)
- Pfizer Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PENBRAYA CI watch — RSS
- PENBRAYA CI watch — Atom
- PENBRAYA CI watch — JSON
- PENBRAYA alone — RSS
- Whole PENBRAYA is a combination vaccine that protects against meningococcal serogroups A, B, C, W, and Y. class — RSS
Cite this brief
Drug Landscape (2026). PENBRAYA — Competitive Intelligence Brief. https://druglandscape.com/ci/penbraya. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing